Breaking News
Get 40% Off 0
💰 Ray Dalio just increased his holdings in Google by 162.61% - See the full portfolio with InvestingPro’s free Stock Ideas tool Copy Portfolios
Close

Indo-Bangla Pharmaceuticals Ltd (INDO)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
14.20 -0.20    -1.39%
08/05 - Closed. Currency in BDT ( Disclaimer )
  • Volume: 327,940
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 14.10 - 14.60
Type:  Equity
Market:  Bangladesh
ISIN:  BD0494IBPL08 
S/N:  IBP
Indo-Bangla Pharmaceuticals 14.20 -0.20 -1.39%

Indo-Bangla Pharmaceuticals Company Profile

 
Read the Indo-Bangla Pharmaceuticals Ltd company profile to learn more about the business and the management team. View Indo-Bangla Pharmaceuticals Ltd facts about employee data, company products and services, and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

224

Equity Type

ORD

Indo-Bangla Pharmaceuticals Limited is a Bangladesh-based pharmaceutical company that provides healthcare services. The Company is engaged in manufacturing and selling of all kinds of medicine (excluding antibiotic), medical preparations drugs and chemicals (human health). It provides production and selling of veterinary medicine. It offers products under various brands, including Tablet Caltab 300mg, Tablet I-Pedom 10mg, Tablet Indophylline 100mg, Tablet sulbumol plus 4.0mg, Tablet Sulbumol 2.0mg, Tablet Albendox 400mg, Tablet Mebendox 100mg, Tablet I-Fol Plus, Tablet I-Fol, Tablet Indosin, Tablet Indo-Fila 100mg, Tablet Indomol Plus, Tablet Trialugel and Tablet ICet 10mg. The Company produces approximately more than 90 brands. Indo-Bangla Pharma’s portfolio encompasses various the categories, including analgesics, respiratory, cardiovascular, central nervous system, dermatology, and gastrointestinal.

Contact Information

Address Plot No. #183, Block #B 7th Floor
Ahmed Akbar Sobhan Road Bashundhara R/A, Baridhara Dhaka,1229
Bangladesh
Phone 880 4 316 1028
Fax -

Top Executives

Name Age Since Title
A. F. M. Anowarul Huq 46 2014 MD & Director
Hafiza Yeasmin 45 2014 Chairman
Fatima Parvin 49 2016 Director
Md. Golam Rabbani - 2017 Nominated Director of Investment Corporation of Bangladesh
Md. Iftikhar-Uz-Zaman 66 2020 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

INDO Price Commentary

Write your thoughts about Indo-Bangla Pharmaceuticals Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Al Kayes
Al Kayes Oct 24, 2019 3:36
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Thu, 2nd May 20199:51 amQ3 Financials(Q3 Un-audited): EPS was Tk. 0.43 for January-March 2019 as against Tk. 0.35 for January-March 2018; EPS was Tk. 1.13 for July 2018-March 2019 as against Tk. 1.02 for July 2017-March 2018. NOCFPS was Tk. 0.98 for July 2018-March 2019 as against Tk. 0.74 for July 2017-March 2018. NAV per share was Tk. 13.16 as on March 31, 2019 and Tk. 14.19 as on June 30, 2018.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email